Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $51.89 USD
Change Today +0.04 / 0.08%
Volume 408.7K
ALR On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

alere inc (ALR) Snapshot

Open
$52.00
Previous Close
$51.85
Day High
$52.50
Day Low
$51.55
52 Week High
08/13/15 - $55.99
52 Week Low
09/5/14 - $34.79
Market Cap
4.4B
Average Volume 10 Days
623.4K
EPS TTM
$-1.11
Shares Outstanding
85.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALERE INC (ALR)

alere inc (ALR) Related Businessweek News

View More BusinessWeek News

alere inc (ALR) Details

Alere Inc. provides point-of-care diagnostics and services for infectious disease, cardiometabolic disease, and toxicology in the United States and internationally. The company operates through Professional Diagnostics and Consumer Diagnostics segments. Its cardiometabolic products and services include tests to assist in the diagnosis and management of various cardiometabolic factors and conditions, including cardiac markers, glucose and HbA1C, cholesterol levels, blood gases, and home monitoring for VAD and oral anticoagulation. These meters and tests are used in hospital urgent care, laboratory, doctor’s office, or at home. The company’s infectious disease products and services comprise tests to assist in the diagnosis and management of infectious diseases, such as HIV, malaria, syphilis, E. coli, and influenza. The infectious disease diagnostic tests and monitoring devices provide results for approximately 75 types of infectious diseases, including those caused by bacteria, viruses, fungi, or parasites. Its drug and alcohol testing portfolio includes rapid analyzer-based tests, visual-read screening devices, laboratory tests, and immunoassay reagents. The company’s toxicology products are used in hospitals, clinics, physician offices, criminal justice systems, workplace, rehabilitation, occupational health clinics, home testing, and other. Alere Inc. also delivers services and solutions across various environments, including clinical immunology, women's health, and oncology. It markets its professional diagnostic products through its sales force and distribution networks; and First Check consumer drug testing products through retail drug stores, drug wholesalers, groceries, and mass merchandisers. The company was formerly known as Inverness Medical Innovations, Inc. and changed its name to Alere Inc. in July 2010. Alere Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

9,800 Employees
Last Reported Date: 05/28/15
Founded in 1981

alere inc (ALR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $882.1K
Global President of Toxicology
Total Annual Compensation: $650.0K
Global President of Cardiometabolic Business ...
Total Annual Compensation: $548.1K
Global President of Infectious Disease Busine...
Total Annual Compensation: $486.3K
Executive officer
Total Annual Compensation: $425.1K
Compensation as of Fiscal Year 2014.

alere inc (ALR) Key Developments

Alere Inc. Declares Cash Dividend on Series B Convertible Perpetual Preferred Stock, Payable on October 15, 2015

Alere Inc. has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock. The dividend is payable on October 15, 2015 to holders of record of Series B stock at the close of business on October 1, 2015. Such payment will cover the amount of all dividends accrued from July 1, 2015 through September 30, 2015.

Alere Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reports Impairments for the Quarter Ended June 30, 2015; Provides Earnings Guidance for the Year Ending December 31, 2015

Alere Inc. reported consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net revenue of $629,156,000 against $647,398,000 a year ago. Operating income was $91,837,000 against operating loss of $5,749,000 a year ago. Income from continuing operations before provision (benefit) for income taxes was $36,603,000 against loss from continuing operations before provision (benefit) for income taxes of $54,564,000 a year ago. Income from continuing operations was $20,263,000 against loss from continuing operations of $57,941,000 a year ago. Net income attributable to the company and subsidiaries was $19,904,000 against net loss attributable to the company and subsidiaries of $45,088,000 a year ago. Income from continuing operations was $0.17 against loss from continuing operations of $0.77 a year ago. Basic and diluted net income per common share was $0.17 against basic and diluted loss per share of $0.61 a year ago. Non-GAAP adjusted operating income was $115,225,000 against $97,264,000 a year ago. Non-GAAP adjusted net income available to common stockholders was $48,250,000 against $36,184,000 a year ago. Non-GAAP adjusted income per diluted common share from continuing operations was $0.54 against $0.39 a year ago. Non-GAAP adjusted net income per diluted common share was $0.54 against $0.42 a year ago. Non-GAAP adjusted net Revenues were $629,356,000 against $647,771,000 a year ago. Non-GAAP EBITDA was $141,260,000. Cash flow from operating activities was $4,148,000. Capital expenditures were $21,637,000. For the six months, the company reported net revenue of $1,237,309,000 against $1,272,637,000 a year ago. Operating income was $119,244,000 against $29,247,000 a year ago. Income from continuing operations before provision (benefit) for income taxes was $16,309,000 against loss from continuing operations before provision (benefit) for income taxes of $64,446,000 a year ago. Income from continuing operations was $12,714,000 against loss from continuing operations of $60,791,000 a year ago. Net income attributable to the company and subsidiaries was $229,044,000 against net loss attributable to the company and subsidiaries of $50,642,000 a year ago. Basic and diluted net income from continuing operations was $0.02 per share against basic and diluted net loss from continuing operations of $0.87 per share a year ago. Basic and diluted net income per common share was $2.54 against basic and diluted loss per share of $0.74 a year ago. Non-GAAP adjusted operating income was $230,003,000 against $206,744,000 a year ago. Non-GAAP adjusted net income available to common stockholders was $94,171,000 against $82,068,000 a year ago. Non-GAAP adjusted income per diluted common share from continuing operations was $1.07 against $0.90 a year ago. Non-GAAP adjusted net income per diluted common share was $1.06 against $0.96 a year ago. Non-GAAP adjusted net revenue was $1,237,756,000 against $1,273,429,000 a year ago. Non-GAAP EBITDA was $273,641,000. Cash flow from operating activities was $32,526,000. Capital expenditures were $47,284,000. For the quarter, the company reported impairment and loss on disposition, net of $5,542,000 against $638,000 a year ago. For the year ending December 31, 2015, the company expects net revenue to be in the range of $2.5 billion to $2.6 billion. Non-GAAP adjusted net income from continuing operations available to common stockholders in the range of $2.40 to $2.50 per diluted share.

Alere Inc. to Report Q2, 2015 Results on Aug 04, 2015

Alere Inc. announced that they will report Q2, 2015 results at 8:30 AM, US Eastern Standard Time on Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALR:US $51.89 USD +0.04

ALR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $137.61 USD +0.59
BioMerieux €98.30 EUR -0.75
PerkinElmer Inc $47.95 USD +0.39
STERIS Corp $64.23 USD +0.45
Teleflex Inc $129.17 USD +1.07
View Industry Companies
 

Industry Analysis

ALR

Industry Average

Valuation ALR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 2.9x
Price/Cash Flow 18.4x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALERE INC, please visit www.alere.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.